Advertisement

Drug-Food Interactions

  • Eric Wenzler
  • Kelly Sprandel-Harris
  • Keith A. Rodvold
Chapter
Part of the Infectious Disease book series (ID)

Abstract

Drug–food interactions can be detrimental to the pharmacologic treatment of infectious diseases by decreasing the efficacy or increasing the toxicity of antimicrobials. Compared to well-known drug–drug interactions, drug–food interactions often go unrecognized and can lead to poor clinical outcomes. In addition to affecting the risk–benefit ratio of the antimicrobial, drug–food interactions can be cumbersome to patients and lead to nonadherence due to interference with daily activities. This chapter will discuss the mechanisms of drug–food interaction, the appropriate methodology for food-effect studies, the specific effects of food on a variety of antimicrobials, as well as the recommended dosing guidelines for administration with regard to meals.

Keywords

Drug–food interactions Pharmacokinetics Pharmacodynamics Absorption Metabolism Meals Food Study design Statistics Penicillins Cephalosporins Macrolides Tetracyclines Fluoroquinolones Anthelmintics  Antimalarials Antimycobacterial agents Antifungal agents Antiviral agents 

References

  1. 1.
    Welling PG, Tse FLS (1982) The influence of food on the absorption of antimicrobial agents. J Antimicrob Chemother 9:7–27PubMedCrossRefGoogle Scholar
  2. 2.
    Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG (1995) Drug-food interactions in clinical practice. J Fam Pract 40:376–384PubMedGoogle Scholar
  3. 3.
    Singh BN (1999) Effects of food on clinical pharmacokinetics. Clin Pharmacokinet 37:213–255PubMedCrossRefGoogle Scholar
  4. 4.
    Krishnaswamy K (1989) Drug metabolism and pharmacokinetics in malnourished children. Clin Pharmacokinet 17:68–88PubMedCrossRefGoogle Scholar
  5. 5.
    Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W, Watkins PB (1997) Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Investig 99:2545–2553PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Bailey DG, Malcolm J, Arnold O, David Spence J (2002) Grapefruit juice-drug interactions. Br J Clin Pharmacol 46:101–110CrossRefGoogle Scholar
  7. 7.
    Dresser G (2002) Fruit juices inhibit organic anion transporting polypeptide–mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 71:11–20PubMedCrossRefGoogle Scholar
  8. 8.
    Takanaga H, Ohnishi A, Matsuo H, Sawada Y (1998) Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells. Biol Pharm Bull 21:1062–1066PubMedCrossRefGoogle Scholar
  9. 9.
    Soldner A, Christians U, Susanto M, Wacher V, Silverman J, Benet L (1999) Grapefruit juice exerts stimulatory effects on P-glycoprotein. Clin Pharmacol Ther 65:205–205CrossRefGoogle Scholar
  10. 10.
    Eshelman FN, Spyker DA (1978) Pharmacokinetics of amoxicillin and ampicillin: crossover study of the effect of food. Antimicrob Agents Chemother 14:539–543PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Staniforth DH, Lillystone RJ, Jackson D (1982) Effect of food on the bioavailability and tolerance of clavulanic acid/amoxycillin combination. J Antimicrob Chemother 10:131–139PubMedCrossRefGoogle Scholar
  12. 12.
    Lode H, Stahlmann R, Koeppe P (1979) Comparative pharmacokinetics of cephalexin, cefaclor, cefadroxil, and CGP 9000. Antimicrob Agents Chemother 16:1–6PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Barbhaiya RH, Shukla UA, Gleason CR, Shyu WC, Pittman KA (1990) Comparison of the effects of food on the pharmacokinetics of cefprozil and cefaclor. Antimicrob Agents Chemother 34:1210–1213PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Shukla UA, Pittman KA, Barbhaiya RH (1992) Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers. J Clin Pharmacol 32:725–731PubMedCrossRefGoogle Scholar
  15. 15.
    Finn A, Straughn A, Meyer M, Chubb J (1987) Effect of dose and food on the bioavailability of cefuroxime axetil. Biopharm Drug Dispos 8:519–526PubMedCrossRefGoogle Scholar
  16. 16.
    Sommers DK, Wyk M, Moncrieff J, Schoeman HS (1984) Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil. Br J Clin Pharmacol 18:535–539PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Hughes GS, Heald DL, Barker KB, Patel RK, Spillers CR, Watts KC, Batts DH, Euler AR (1989) The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil. Clin Pharmacol Ther 46:674–685PubMedCrossRefGoogle Scholar
  18. 18.
    Nakashima M, Uematsu T, Takiguchi Y, Kanamaru M (1987) Phase I study of cefixime, a new oral cephalosporin. J Clin Pharmacol 27:425–431PubMedCrossRefGoogle Scholar
  19. 19.
    Faulkner RD, Bohaychuk W, Haynes JD, Desjardins RE, Yacobi A, Silber BM (1988) The pharmacokinetics of cefixime in the fasted and fed state. Eur J Clin Pharmacol 34:525–528PubMedCrossRefGoogle Scholar
  20. 20.
    Li JT, Hou F, Lu H, Li TY, Li H (1997) Phase I clinical trial of cefditoren pivoxil (ME 1207): pharmacokinetics in healthy volunteers. Drugs Exp Clin Res 23:145–150PubMedGoogle Scholar
  21. 21.
    Barr WH, Lin C-C, Radwanski E, Lim J, Symchowicz S, Affrime M (1991) The pharmacokinetics of ceftibuten in humans. Diagn Microbiol Infect Dis 14:93–100PubMedCrossRefGoogle Scholar
  22. 22.
    Hovi T, Heikinheimo M (1985) Effect of concomitant food intake on absorption kinetics of erythromycin in healthy volunteers. Eur J Clin Pharmacol 28:231–233PubMedCrossRefGoogle Scholar
  23. 23.
    DiSanto AR, Chodos DJ (1981) Influence of study design in assessing food effects on absorption of erythromycin base and erythromycin stearate. Antimicrob Agents Chemother 20:190–196PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Clayton D, Leslie A (1981) The bioavailability of erythromycin stearate versus enteric-coated erythromycin base when taken immediately before and after food. J Int Med Res 9:470–477PubMedCrossRefGoogle Scholar
  25. 25.
    Rutland J, Berend N, Marlin GE (1979) The influence of food on the bioavailability of new formulations of erythromycin stearate and base. Br J Clin Pharmacol 8:343–347PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Welling PG, Huang H, Hewitt PF, Lyons LL (1978) Bioavailability of erythromycin stearate: influence of food and fluid volume. J Pharm Sci 67:764–766PubMedCrossRefGoogle Scholar
  27. 27.
    Thompson PJ, Burgess KR, Marlin GE (1980) Influence of food on absorption of erythromycin ethyl succinate. Antimicrob Agents Chemother 18:829–831PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Chu S-Y, Park Y, Locke C, Wilson DS, Cavanaugh JC (1992) Drug-food interaction potential of clarithromycin, a new macrolide antimicrobial. J Clin Pharmacol 32:32–36PubMedCrossRefGoogle Scholar
  29. 29.
    Guay D. RP (2001) Pharmacokinetics and tolerability of extended-release clarithromycin. Clin Ther 23:566–577PubMedCrossRefGoogle Scholar
  30. 30.
    Foulds G, Luke DR, Teng R, Willavize SA, Friedman H, Curatolo WJ (1996) The absence of an effect of food on the bioavailability of azithromycin administered as tablets, sachet or suspension. J Antimicrob Chemother 37:37–44PubMedCrossRefGoogle Scholar
  31. 31.
    Bhargava V, Lenfant B, Perret C, Pascual MH, Sultan E, Montay G (2002) Lack of effect of food on the bioavailability of a new ketolide antibacterial, telithromycin. Scand J Infect Dis 34:823–826PubMedCrossRefGoogle Scholar
  32. 32.
    Welling PG, Koch PA, Lau CC, Craig WA (1977) Bioavailability of tetracycline and doxycycline in fasted and nonfasted subjects. Antimicrob Agents Chemother 11:462–469PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Leyden JJ (1985) Absorption of minocycline hydrochloride and tetracycline hydrochloride. J Am Acad Dermatol 12:308–312PubMedCrossRefGoogle Scholar
  34. 34.
    Frost RW, Carlson JD, Dietz AJ Jr, Heyd A, Lettieri JT (1989) Ciprofloxacin pharmacokinetics after a standard or high-fat/high-calcium breakfast. J Clin Pharmacol 29:953–955PubMedCrossRefGoogle Scholar
  35. 35.
    Allen A, Bygate E, Clark D, Lewis A, Pay V (2000) The effect of food on the bioavailability of oral gemifloxacin in healthy volunteers. Int J Antimicrob Agents 16:45–50PubMedCrossRefGoogle Scholar
  36. 36.
    Lee LJ, Hafkin B, Lee ID, Hoh J, Dix R (1997) Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects. Antimicrob Agents Chemother 41:2196–2200PubMedPubMedCentralGoogle Scholar
  37. 37.
    Lettieri J, Vargas R, Agarwal V, Liu P (2001) Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400mg in healthy male volunteers. Clin Pharmacokinet 40:19–25PubMedCrossRefGoogle Scholar
  38. 38.
    Leroy A, Borsa F, Humbert G, Bernadet P, Fillastre JP (1987) The pharmacokinetics of ofloxacin in healthy adult male volunteers. Eur J Clin Pharmacol 31:629–630PubMedCrossRefGoogle Scholar
  39. 39.
    Nagy J, Schipper HG, Koopmans RP, Butter JJ, Van Boxtel CJ, Kager PA (2002) Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability. Am J Trop Med Hyg 66:260–263PubMedCrossRefGoogle Scholar
  40. 40.
    Guzzo CA, Furtek CI, Porras AG, Chen C, Tipping R, Clineschmidt CM, Sciberras DG, Hsieh JYK, Lasseter KC (2002) Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol 42:1122–1133PubMedCrossRefGoogle Scholar
  41. 41.
    Castro N, Medina R, Sotelo J, Jung H (2000) Bioavailability of praziquantel increases with concomitant administration of food. Antimicrob Agents Chemother 44:2903–2904PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Cuong BT, Binh VQ, Dai B, Duy DN, Lovell CM, Rieckmann KH, Edstein MD (2006) Does gender, food or grapefruit juice alter the pharmacokinetics of primaquine in healthy subjects? Br J Clin Pharmacol 61:682–689PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Tulpule A, Krishnaswamy K (1982) Effect of food on bioavailability of chloroquine. Eur J Clin Pharmacol 23:271–273PubMedCrossRefGoogle Scholar
  44. 44.
    Crevoisier C, Handschin J, Barré J, Roumenov D, Kleinbloesem C (1997) Food increases the bioavailability of mefloquine. Eur J Clin Pharmacol 53:135–139PubMedCrossRefGoogle Scholar
  45. 45.
    Falloon J, Sargent S, Piscitelli SC, Bechtel C, LaFon SW, Sadler B, Walker RE, Kovacs JA, Polis MA, Davey RT, Lane HC, Masur H (1999) Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study. Pharmacotherapy 19:1050–1056PubMedCrossRefGoogle Scholar
  46. 46.
    McGehee RF, Smith CB, Wilcox C, Finland M (1968) Comparative studies of antibacterial activity in vitro and absorption and excretion of lincomycin and clinimycin. Am J Med Sci 256:279–292PubMedCrossRefGoogle Scholar
  47. 47.
    Borgia M, Longo A, Lodola E (1989) Relative bioavailability of fosfomycin and of trometamol after administration of single dose by oral route of fosfomycin trometamol in fasting conditions and after a meal. Int J Clin Pharmacol Ther Toxicol 27:411–417PubMedGoogle Scholar
  48. 48.
    Bergogne-Berezin E, Muller-Serieys C, Joly-Guillou ML, Dronne N (1987) Trometamol-fosfomycin (Monuril) bioavailability and food-drug interaction. Eur Urol 13(Suppl 1):64–68PubMedCrossRefGoogle Scholar
  49. 49.
    Stockis A, Allemon AM, De Bruyn S, Gengler C (2002) Nitazoxanide pharmacokinetics and tolerability in man using single ascending oral doses. Int J Clin Pharmacol Ther 40:213–220PubMedCrossRefGoogle Scholar
  50. 50.
    Melander A, Kahlmeter G, Kamme C, Ursing B (1977) Bioavailability of metronidazole in fasting and non-fasting healthy subjects and in patients with Crohn’s disease. Eur J Clin Pharmacol 12:69–72PubMedCrossRefGoogle Scholar
  51. 51.
    Welshman IR, Sisson TA, Jungbluth GL, Stalker DJ, Hopkins NK (2001) Linezolid absolute bioavailability and the effect of food on oral bioavailability. Biopharm Drug Dispos 22:91–97PubMedCrossRefGoogle Scholar
  52. 52.
    Flanagan SD, Bien PA, Munoz KA, Minassian SL, Prokocimer PG (2014) Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug. Pharmacotherapy 34:240–250PubMedCrossRefGoogle Scholar
  53. 53.
    Hoppu K, Tuomisto J, Koskimies O, Simell O (1987) Food and guar decrease absorption of trimethoprim. Eur J Clin Pharmacol 32:427–429PubMedCrossRefGoogle Scholar
  54. 54.
    Peloquin CA, Namdar R, Dodge AA, Nix DE (1999) Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. Int J Tuberc Lung Dis 3:703–710PubMedGoogle Scholar
  55. 55.
    Peloquin CA, Namdar R, Singleton MD, Nix DE (1999) Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 115:12–18PubMedCrossRefGoogle Scholar
  56. 56.
    Narang PK, Lewis RC, Bianchine JR (1992) Rifabutin absorption in humans: relative bioavailability and food effect. Clin Pharmacol Ther 52:335–341PubMedCrossRefGoogle Scholar
  57. 57.
    Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, Childs JM, Nix DE (1999) Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob Agents Chemother 43:568–572PubMedPubMedCentralGoogle Scholar
  58. 58.
    Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, James GT, Nix DE (1998) Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. Pharmacotherapy 18:1205–1211PubMedGoogle Scholar
  59. 59.
    Peloquin CA, Zhu M, Adam RD, Singleton MD, Nix DE (2001) Pharmacokinetics of para-aminosalicylic acid granules under four dosing conditions. Ann Pharmacother 35:1332–1338PubMedCrossRefGoogle Scholar
  60. 60.
    Zhu M, Nix DE, Adam RD, Childs JM, Peloquin CA (2001) Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids. Pharmacotherapy 21:891–897PubMedCrossRefGoogle Scholar
  61. 61.
    Auclair B, Nix DE, Adam RD, James GT, Peloquin CA (2001) Pharmacokinetics of ethionamide administered under fasting conditions or with orange juice, food, or antacids. Antimicrob Agents Chemother 45:810–814PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Teo SK, Scheffler MR, Kook KA, Tracewell WG, Colburn WA, Stirling DI, Thomas SD (2000) Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women. Biopharm Drug Dispos 21:33–40PubMedCrossRefGoogle Scholar
  63. 63.
    Nix DE, Adam RD, Auclair B, Krueger TS, Godo PG, Peloquin CA (2004) Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. Tuberculosis (Edinb) 84:365–373CrossRefGoogle Scholar
  64. 64.
    Nedelman J, Cramer JA, Robbins B, Gibiansky E, Chang CT, Gareffa S, Cohen A, Meligeni J (1997) The effect of food on the pharmacokinetics of multiple-dose terbinafine in young and elderly healthy subjects. Biopharm Drug Dispos 18:127–138PubMedCrossRefGoogle Scholar
  65. 65.
    Daneshmend TK, Warnock DW, Ene MD, Johnson EM, Potten MR, Richardson MD, Williamson PJ (1984) Influence of food on the pharmacokinetics of ketoconazole. Antimicrob Agents Chemother 25:1–3PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Zimmermann T, Yeates RA, Laufen H, Pfaff G, Wildfeuer A (1994) Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol 46:147–150PubMedCrossRefGoogle Scholar
  67. 67.
    Purkins L, Wood N, Kleinermans D, Greenhalgh K, Nichols D (2003) Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol 56:17–23PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M (2003) Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 57:218–222CrossRefGoogle Scholar
  69. 69.
    Krishna G, Ma L, Martinho M, O’Mara E (2012) Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob Agents Chemother 56:4196–4201PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Krishna G, Moton A, Ma L, Medlock MM, McLeod J (2008) Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 53:958–966PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Kersemaekers WM, Dogterom P, Xu J, Marcantonio EE, de Greef R, Waskin H, van Iersel ML (2015) Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation. Antimicrob Agents Chemother 59:3385–3389PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Schmitt-Hoffmann A, Desai A, Kowalski D, Pearlman H, Yamazaki T, Townsend R (2016) Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH. Int J Clin Pharmacol Ther 54:572–580PubMedCrossRefGoogle Scholar
  73. 73.
    Aoyagi N, Ogata H, Kaniwa N, Ejima A (1982) Effect of food on the bioavailability of griseofulvin from microsize and PEG ultramicrosize (GRIS-PEG) plain tablets. J Pharmacobiodyn 5:120–124PubMedCrossRefGoogle Scholar
  74. 74.
    Shyu WC, Knupp CA, Pittman KA, Dunkle L, Barbhaiya RH (1991) Food-induced reduction in bioavailability of didanosine. Clin Pharmacol Ther 50:503–507PubMedCrossRefGoogle Scholar
  75. 75.
    Damle BD, Yan J-H, Behr D, O’Mara E, Nichola P, Kaul S, Knupp C (2002) Effect of food on the oral bioavailability of didanosine from encapsulated enteric-coated beads. J Clin Pharmacol 42:419–427PubMedCrossRefGoogle Scholar
  76. 76.
    Shelton MJ, Portmore A, Blum MR, Sadler BM, Reichman RC, Morse GD (1994) Prolonged, but not diminished, zidovudine absorption induced by a high-fat breakfast. Pharmacotherapy 14:671–677PubMedGoogle Scholar
  77. 77.
    Moore KHP, Shaw S, Laurent AL, Lloyd P, Duncan B, Morris DM, O’Mara MJ, Pakes GE (1999) Lamivudine/Zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption. J Clin Pharmacol 39:593–605PubMedCrossRefGoogle Scholar
  78. 78.
    Kaul S, Christofalo B, Raymond RH, Stewart MB, Macleod CM (1998) Effect of food on the bioavailability of stavudine in subjects with human immunodeficiency virus infection. Antimicrob Agents Chemother 42:2295–2298PubMedPubMedCentralGoogle Scholar
  79. 79.
    Chittick GE, Gillotin C, McDowell JA, Lou Y, Edwards KD, Prince WT, Stein DS (1999) Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of food. Pharmacotherapy 19:932–942PubMedCrossRefGoogle Scholar
  80. 80.
    Custodio JM, Yin X, Hepner M, Ling KH, Cheng A, Kearney BP, Ramanathan S (2014) Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection. J Clin Pharmacol 54:378–385PubMedCrossRefGoogle Scholar
  81. 81.
    Lamorde M, Byakika-Kibwika P, Tamale WS, Kiweewa F, Ryan M, Amara A, Tjia J, Back D, Khoo S, Boffito M, Kityo C, Merry C (2012) Effect of food on the steady-state pharmacokinetics of tenofovir and emtricitabine plus efavirenz in Ugandan adults. AIDS Res Treat 2012:105980PubMedPubMedCentralGoogle Scholar
  82. 82.
    Kaul S, Ji P, Lu M, Nguyen KL, Shangguan T, Grasela D (2010) Bioavailability in healthy adults of efavirenz capsule contents mixed with a small amount of food. Am J Health Syst Pharm 67:217–222PubMedCrossRefGoogle Scholar
  83. 83.
    Schöller-Gyüre M, Boffito M, Pozniak AL, Leemans R, Kakuda TN, Woodfall B, Vyncke V, Peeters M, Vandermeulen K, Hoetelmans RMW (2008) Effects of different meal compositions and fasted state on the oral bioavailability of etravirine. Pharmacotherapy 28:1215–1222PubMedCrossRefGoogle Scholar
  84. 84.
    Crauwels HM, van Heeswijk RP, Buelens A, Stevens M, Boven K, Hoetelmans RM (2013) Impact of food and different meal types on the pharmacokinetics of rilpivirine. J Clin Pharmacol 53:834–840PubMedCrossRefGoogle Scholar
  85. 85.
    Lamorde M, Walimbwa S, Byakika-Kibwika P, Katwere M, Mukisa L, Sempa JB, Else L, Back DJ, Khoo SH, Merry C (2015) Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults. J Antimicrob Chemother 70:1482–1486PubMedCrossRefGoogle Scholar
  86. 86.
    Yeh KC, Deutsch PJ, Haddix H, Hesney M, Hoagland V, WD J, Justice SJ, Osborne B, Sterrett AT, Stone JA, Woolf E, Waldman S (1998) Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob Agents Chemother 42:332–338PubMedPubMedCentralGoogle Scholar
  87. 87.
    Kakuda TN, Falcon RW (2006) Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers. Pharmacotherapy 26:1060–1068PubMedCrossRefGoogle Scholar
  88. 88.
    Hugen PW, Burger DM, Koopmans PP, Stuart JW, Kroon FP, van Leusen R, Hekster YA (2002) Saquinavir soft-gel capsules (Fortovase) give lower exposure than expected, even after a high-fat breakfast. Pharm World Sci 24:83–86PubMedCrossRefGoogle Scholar
  89. 89.
    Kaeser B, Charoin JE, Gerber M, Oxley P, Birnboeck H, Saiedabadi N, Banken L (2005) Assessment of the bioequivalence of two nelfinavir tablet formulations under fed and fasted conditions in healthy subjects. Int J Clin Pharmacol Ther 43:154–162PubMedCrossRefGoogle Scholar
  90. 90.
    Saah AJ, Winchell GA, Nessly ML, Seniuk MA, Rhodes RR, Deutsch PJ (2001) Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteers. Antimicrob Agents Chemother 45:2710–2715PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Veldkamp AI, van Heeswijk RP, Mulder JW, Meenhorst PL, Schreij G, van der Geest S, Lange JM, Beijnen JH, Hoetelmans RM (2001) Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals. J Acquir Immune Defic Syndr 27:344–349PubMedCrossRefGoogle Scholar
  92. 92.
    Falcoz C, Jenkins JM, Bye C, Hardman TC, Kenney KB, Studenberg S, Fuder H, Prince WT (2002) Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers. J Clin Pharmacol 42:887–898PubMedCrossRefGoogle Scholar
  93. 93.
    Lamorde M, Byakika-Kibwika P, Boffito M, Nabukeera L, Mayito J, Ogwal-Okeng J, Tjia J, Back D, Khoo S, Ryan M, Merry C (2012) Steady-state pharmacokinetics of lopinavir plus ritonavir when administered under different meal conditions in HIV-infected Ugandan adults. J Acquir Immune Defic Syndr 60:295–298PubMedCrossRefGoogle Scholar
  94. 94.
    Oki T, Usami Y, Nakai M, Sagisaka M, Ito H, Nagaoka K, Mamiya N, Yamanaka K, Utsumi M, Kaneda T (2004) Pharmacokinetics of lopinavir after administration of Kaletra in healthy Japanese volunteers. Biol Pharm Bull 27:261–265PubMedCrossRefGoogle Scholar
  95. 95.
    Sevinsky H, Tao X, Wang R, Ravindran P, Sims K, Xu X, Jariwala N, Bertz R (2015) A randomized trial in healthy subjects to assess the bioequivalence of an atazanavir/cobicistat fixed-dose combination tablet versus administration as separate agents. Antivir Ther 20:493–500PubMedCrossRefGoogle Scholar
  96. 96.
    Sekar V, Kestens D, Spinosa-Guzman S, De Pauw M, De Paepe E, Vangeneugden T, Lefebvre E, Hoetelmans RMW (2007) The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers. J Clin Pharmacol 47:479–484PubMedCrossRefGoogle Scholar
  97. 97.
    Brainard DM, Friedman EJ, Jin B, Breidinger SA, Tillan MD, Wenning LA, Stone JA, Chodakewitz JA, Wagner JA, Iwamoto M (2011) Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics. J Clin Pharmacol 51:422–427PubMedCrossRefGoogle Scholar
  98. 98.
    Song I, Borland J, Chen S, Patel P, Wajima T, Peppercorn A, Piscitelli SC (2012) Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother 56:1627–1629PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    Shiomi M, Matsuki S, Ikeda A, Ishikawa T, Nishino N, Kimura M, Irie S (2014) Effects of a protein-rich drink or a standard meal on the pharmacokinetics of elvitegravir, cobicistat, emtricitabine and tenofovir in healthy Japanese male subjects: a randomized, three-way crossover study. J Clin Pharmacol 54:640–648PubMedCrossRefGoogle Scholar
  100. 100.
    Sun DQ, Wang HS, Ni MY, Wang BJ, Guo RC (2007) Pharmacokinetics, safety and tolerance of single- and multiple-dose adefovir dipivoxil in healthy Chinese subjects. Br J Clin Pharmacol 63:15–23PubMedCrossRefGoogle Scholar
  101. 101.
    Zhou XJ, Lloyd DM, Chao GC, Brown NA (2006) Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects. J Clin Pharmacol 46:275–281PubMedCrossRefGoogle Scholar
  102. 102.
    Anonymous. Food and drug administration center for drug evaluation and research clinical pharmacology and biopharmaceutics review: Application Number 201917Orig1s000. Telaprevir. 22 November 2010. Available from http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201917Orig1s000ClinPharmR.pdf. Accessed 19 March 2017
  103. 103.
    German P, Mathias A, Brainard D, Kearney BP (2016) Clinical pharmacokinetics and pharmacodynamics of ledipasvir/sofosbuvir, a fixed-dose combination tablet for the treatment of hepatitis C. Clin Pharmacokinet 55:1337–1351PubMedCrossRefGoogle Scholar
  104. 104.
    Mogalian E, German P, Kearney BP, Yang CY, Brainard D, Link J, McNally J, Han L, Ling J, Mathias A (2017) Preclinical pharmacokinetics and first-in-human pharmacokinetics, safety, and tolerability of velpatasvir, a pangenotypic HCV NS5A inhibitor, in healthy subjects. Antimicrob Agents Chemother.  https://doi.org/10.1128/AAC.02084-16
  105. 105.
    Wills RJ, Rodriguez LC, Choma N, Oakes M (1987) Influence of a meal on the bioavailability of rimantadine.HCl. J Clin Pharmacol 27:821–823PubMedCrossRefGoogle Scholar
  106. 106.
    Brown F, Banken L, Saywell K, Arum I (1999) Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. Clin Pharmacokinet 37:167–176PubMedCrossRefGoogle Scholar
  107. 107.
    Gill KS, Wood MJ (1996) The clinical pharmacokinetics of famciclovir. Clin Pharmacokinet 31:1–8PubMedCrossRefGoogle Scholar
  108. 108.
    Cronk GA, Wheatley WB, Fellers GF, Albright H (1960) The relationship of food intake to the absorption of potassium alpha-phenoxyethyl penicillin and potassium phenoxymethyl penicillin from the gastrointestinal tract. Am J Med Sci 241:125–131CrossRefGoogle Scholar
  109. 109.
    Welling PG, Huang H, Koch PA, Craig WA, Madsen PO (1977) Bioavailability of ampicillin and amoxicillin in fasted and nonfasted subjects. J Pharm Sci 66:549–552PubMedCrossRefGoogle Scholar
  110. 110.
    Ali HM, Farouk AM (1980) The effect of sudanese diet on the bioavailability of ampicillin. Int J Pharm 6:301–306CrossRefGoogle Scholar
  111. 111.
    Neu HC (1974) Antimicrobial activity and human pharmacology of amoxicillin. J Infect Dis 129:S123–S131CrossRefGoogle Scholar
  112. 112.
    Anonymous. MOXATAG (amoxicillin extended-release tablets) [package insert]. Germantown, MD; Middlebrook Pharmaceuticals, Inc. Revised December 2008. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6c0e721-2021-4983-a305-49bdf8f135a9. Accessed 20 March 2017
  113. 113.
    Anonymous. AUGMENTIN (amoxicillin/clavulanate potassium) [package insert]. Research Triangle Park, NC; Glaxo Smith Kline. Revised May 2002. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050575s037550597s044050725s025050726s019lbl.pdf. Accessed 20 March 2017
  114. 114.
    Anonymous. AUGMENTIN-ES (amoxicillin/clavulanate potassium) [package insert]. Research Triangle Park, NC; Glaxo Smith Kline. Revised November 2006. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050755s014lbl.pdf. Accessed 20 March 2017
  115. 115.
    Anonymous. DYNAPEN (dicloxacillin) [package insert]. North Wales, PA; Teva Pharmaceuticals, Inc. Revised June 2016. Available from: https://www.drugs.com/pro/dicloxacillin.html. Accessed 20 March 2017
  116. 116.
    Gower PE, Dash CH (1969) Cephalexin: human studies of absorption and excretion of a new cephalosporin antibiotic. Br J Pharmacol 37:738–747PubMedPubMedCentralCrossRefGoogle Scholar
  117. 117.
    Tetzlaff TR, McCracken GH, Thomas ML (1978) Bioavailability of cephalexin in children: relationship to drug formulations and meals. J Pediatr 92:292–294PubMedCrossRefGoogle Scholar
  118. 118.
    Sourgens H, Derendorf H, Schifferer H (1997) Pharmacokinetic profile of cefaclor. Int J Clin Pharmacol Ther 35:374–380PubMedGoogle Scholar
  119. 119.
    Glynne A, Goulbourn RA, Ryden R (1978) A human pharmacology study of cefaclor. J Antimicrob Chemother 4:343–348PubMedCrossRefGoogle Scholar
  120. 120.
    Oguma T, Yamada H, Sawaki M, Narita N (1991) Pharmacokinetic analysis of the effects of different foods on absorption of cefaclor. Antimicrob Agents Chemother 35:1729–1735PubMedPubMedCentralCrossRefGoogle Scholar
  121. 121.
    Anonymous. CECLOR (cefaclor) [package insert]. Indianapolis, IN; Eli Lilly and Company. Revised March 2003. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf. Accessed 20 March 2017
  122. 122.
    Ginsburg CM, McCracken GH, Petruska M, Olson K (1985) Pharmacokinetics and bactericidal activity of cefuroxime axetil. Antimicrob Agents Chemother 28:504–507PubMedPubMedCentralCrossRefGoogle Scholar
  123. 123.
    Fassbender M, Lode H, Schaberg T, Borner K, Koeppe P (1993) Pharmacokinetics of new oral cephalosporins, including a new carbacephem. Clin Infect Dis 16:646–653PubMedCrossRefGoogle Scholar
  124. 124.
    Borin MT, Driver MR, Forbes KK (1995) Effect of timing of food on absorption of cefpodoxime proxetil. J Clin Pharmacol 35:505–509PubMedCrossRefGoogle Scholar
  125. 125.
    Guay DRP (2000) Pharmacodynamics and pharmacokinetics of cefdinir, an oral extended spectrum cephalosporin. Pediatr Infect Dis J 19:S141–S146PubMedCrossRefGoogle Scholar
  126. 126.
    Anonymous. OMNICEF (cefdinir) [package insert]. Chicago, IL; Abbott Laboratories. Revised June 2007. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050739s015,050749s021lbl.pdf. Accessed 20 March 2017
  127. 127.
    Anonymous. SPECTRACEF (cefditoren pivoxil) [package insert]. Stamford, CT; Purdue Pharmaceutical Products, LP. Revised December 2005. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021222s009lbl.pdf. Accessed 20 March 2017
  128. 128.
    Kearns GL, Young RA (1994) Ceftibuten pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 26:169–189PubMedCrossRefGoogle Scholar
  129. 129.
    Bechtol LDBC, Perkal MB (1979) The influence of food on the absorption of erythromycin esters and enteric-coated erythromycin in single-dose studies. Curr Ther Res 25:618–625Google Scholar
  130. 130.
    Hirsch HA, Finland M (1959) Effect of food on the absorption of erythromycin propionate, erythromycin stearate and triacetyloleandomycin. Am J Med Sci 237:693–709PubMedCrossRefGoogle Scholar
  131. 131.
    Clapper WE, Mostyn M, Meade GH (1960) An evaluation of erythromycin stearate and propionyl erythromycin in normal and hospitalized subjects. Antibiotic Med Clin Ther (New York) 7:91–96Google Scholar
  132. 132.
    Coyne TC, Shum SHU, Chun AHC, Jeansonne L, Shirkey HC (1978) Bioavailability of erythromycin ethylsuccinate in pediatric patients. J Clin Pharmacol 18:194–202PubMedCrossRefGoogle Scholar
  133. 133.
    Kanazawa S, Ohkubo T, Sugawara K (2001) The effects of grapefruit juice on the pharmacokinetics of erythromycin. Eur J Clin Pharmacol 56:799–803PubMedCrossRefGoogle Scholar
  134. 134.
    Cheng KL, Nafziger AN, Peloquin CA, Amsden GW (1998) Effect of grapefruit juice on clarithromycin pharmacokinetics. Antimicrob Agents Chemother 42:927–929PubMedPubMedCentralGoogle Scholar
  135. 135.
    Anonymous. BIAXIN (clarithromycin) [package insert]. Chicago, IL; Abbott Laboratories. Revised May 2003. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050662s044s050,50698s026s030,050775s015s019lbl.pdf. Accessed 20 March 2017
  136. 136.
    Hopkins S (1991) Clinical toleration and safety of azithromycin. Am J Med 91:S40–S45CrossRefGoogle Scholar
  137. 137.
    Agouridas C, Denis A, Auger JM, Benedetti Y, Bonnefoy A, Bretin F, Chantot JF, Dussarat A, Fromentin C, D'Ambrieres SG, Lachaud S, Laurin P, Le Martret O, Loyau V, Tessot N (1998) Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. J Med Chem 41:4080–4100PubMedCrossRefGoogle Scholar
  138. 138.
    Anonymous. Ketek (telithromycin) [package insert]. Bridgewater, NJ, USA; Sanofi-Aventis. Revised December 2015. Available from http://products.sanofi.us/ketek/ketek.pdf. Accessed 27 January 2016
  139. 139.
  140. 140.
    Jonas M, Cunha BA (1982) Minocycline. Ther Drug Monit 4:115–146CrossRefGoogle Scholar
  141. 141.
    Neuvonen PJ (1976) Interactions with the absorption of tetracyclines. Drugs 11:45–54PubMedCrossRefGoogle Scholar
  142. 142.
    Von Wittenau S (1968) Some pharmacokinetic aspects of doxycycline metabolism in man. Chemotherapy 13:41–50CrossRefGoogle Scholar
  143. 143.
    Meyer FP, Specht H, Quednow B, Walther H (1989) Influence of milk on the bioavailability of doxycycline — new aspects. Infection 17:245–246PubMedCrossRefGoogle Scholar
  144. 144.
    Neuvonen PJ, Penttilä O. (1974) Effect of oral ferrous sulphate on the half-life of doxycycline in man. Eur J Clin Pharmacol 7:361–363PubMedCrossRefGoogle Scholar
  145. 145.
    Allen JC (1976) Minocycline. Ann Intern Med 85:482–487PubMedCrossRefGoogle Scholar
  146. 146.
    Cunha BA, Sibley CM, Ristuccia AM (1982) Doxycycline. Ther Drug Monit 4:115PubMedCrossRefGoogle Scholar
  147. 147.
    Anonymous. DECLOMYCIN (demeclocycline) [package insert]. Manati, Puerto Rico; Mova Pharmaceuticals, Corp. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050261s100lbl.pdf. Accessed 20 March 2017
  148. 148.
    Shah A (1999) Oral bioequivalence of three ciprofloxacin formulations following single-dose administration: 500 mg tablet compared with 500 mg/10 mL or 500 mg/5 mL suspension and the effect of food on the absorption of ciprofloxacin oral suspension. J Antimicrob Chemother 43:49–54PubMedCrossRefGoogle Scholar
  149. 149.
    Anonymous. CIPRO (ciprofloxacin) [package insert]. Whippany, NJ; Bayer Healthcare Pharmaceuticals, Inc. Revised July 2016. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019537s086lbl.pdf. Accessed 20 March 2017
  150. 150.
    Stass H, Kubitza D (2001) Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans. Clin Pharmacokinet 40:57–62PubMedCrossRefGoogle Scholar
  151. 151.
    Anonymous. AVELOX (moxifloxacin) [package insert]. Whippany, NJ; Bayer Healthcare Pharmaceuticals, Inc. Revised July 2016. Available from: https://www.merck.com/product/usa/pi_circulars/a/avelox/avelox_pi.pdf. Accessed 20 March 2017
  152. 152.
    Anonymous. LEVAQUIN (levofloxacin) [package insert]. Titusville, NJ; Janssen Pharmaceuticals, Inc. Revised September 2008. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020634s065,020635s071,021721s032lbl.pdf. Accessed 20 March 2017
  153. 153.
    Kawakami J, Matsuse T, Kotaki H, Seino T, Fukuchi Y, Orimo H, Sawada Y, Iga T (1994) The effect of food on the interaction of ofloxacin with sucralfate in healthy volunteers. Eur J Clin Pharmacol 47:67–69PubMedCrossRefGoogle Scholar
  154. 154.
    Verho M, Malerczyk V, Dagrosa E, Korn A (1986) The effect of food on the pharmacokinetics of ofloxacin. Curr Med Res Opin 10:166–171PubMedCrossRefGoogle Scholar
  155. 155.
    Kalager T, Digranes A, Bergan T, Rolstad T (1986) Ofloxacin: serum and skin blister fluid pharmacokinetics in the fasting and non-fasting state. J Antimicrob Chemother 17:795–800PubMedCrossRefGoogle Scholar
  156. 156.
    Dudley MN, Marchbanks CR, Flor SC, Beals B (1991) The effect of food or milk on the absorption kinetics of ofloxacin. Eur J Clin Pharmacol 41:569–571PubMedCrossRefGoogle Scholar
  157. 157.
    Anonymous. FLOXIN (ofloxacin) [package insert]. Titusville, NJ; Ortho-McNeil-Janssen Therapeutics, Inc. Revised September 208. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019735s059lbl.pdf. Accessed 20 March 2017
  158. 158.
    Ledergerber B, Bettex JD, Joos B, Flepp M, Luthy R (1985) Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. Antimicrob Agents Chemother 27:350–352PubMedPubMedCentralCrossRefGoogle Scholar
  159. 159.
    Shah A, Liu MC, Vaughan D, Heller AH (1999) Oral bioequivalence of three ciprofloxacin formulations following single-dose administration: 500 mg tablet compared with 500 mg/10 mL or 500 mg/5 mL suspension and the effect of food on the absorption of ciprofloxacin oral suspension. J Antimicrob Chemother 43(Suppl A):49–54PubMedCrossRefGoogle Scholar
  160. 160.
    Martin SJ, Meyer JM, Chuck SK, Jung R, Messick CR, Pendland SL (1998) Levofloxacin and sparfloxacin: new quinolone antibiotics. Ann Pharmacother 32:320–336PubMedCrossRefGoogle Scholar
  161. 161.
    Ballow C, Lettieri J, Agarwal V, Liu P, Stass H, Sullivan JT (1999) Absolute bioavailability of moxifloxacin. Clin Ther 21:513–522PubMedCrossRefGoogle Scholar
  162. 162.
    Anonymous. FACTIVE (gemifloxacin mesylate) [package insert]. Waltham, MA; Oscient Pharmaceuticals Corporation. Revised May 2007. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021158s007lbl.pdf. Accessed 20 March 2017
  163. 163.
    Hoogkamer JFW, Kleinbloesem CH (1995) The effect of milk consumption on the pharmacokinetics of fleroxacin and ciprofloxacin in healthy volunteers. Drugs 49:346–348PubMedCrossRefGoogle Scholar
  164. 164.
    Neuvonen PJ, Kivistö KT, Lehto P (1991) Interference of dairy products with the absorption of ciprofloxacin. Clinical Pharmacology & Therapeutics 50:498–502CrossRefGoogle Scholar
  165. 165.
    Minami R, Inotsume N, Nakano M, Sudo Y, Higashi A, Matsuda I (1993) Effect of milk on absorption of norfloxacin in healthy volunteers. J Clin Pharmacol 33:1238–1240PubMedCrossRefGoogle Scholar
  166. 166.
    Kivisto KT, Ojala-Karlsson P, Neuvonen PJ (1992) Inhibition of norfloxacin absorption by dairy products. Antimicrob Agents Chemother 36:489–491PubMedPubMedCentralCrossRefGoogle Scholar
  167. 167.
    Neuvonen PJ, Kivisto KT (1992) Milk and yoghurt do not impair the absorption of ofloxacin. Br J Clin Pharmacol 33:346–348PubMedPubMedCentralCrossRefGoogle Scholar
  168. 168.
    Stass H, Kubitza D (2001) Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. Clin Pharmacokinet 40:33–38PubMedCrossRefGoogle Scholar
  169. 169.
    Neuhofel AL, Wilton JH, Victory JM, Hejmanowski LG, Amsden GW (2002) Lack of bioequivalence of ciprofloxacin when administered with calcium-fortified orange juice: a new twist on an old interaction. J Clin Pharmacol 42:461–466PubMedCrossRefGoogle Scholar
  170. 170.
    Aminimanizani A, Beringer P, Jelliffe R (2001) Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. Clin Pharmacokinet 40:169–187PubMedCrossRefGoogle Scholar
  171. 171.
    Amsden GW, Whitaker A-M, Johnson PW (2003) Lack of bioequivalence of levofloxacin when coadministered with a mineral-fortified breakfast of juice and cereal. J Clin Pharmacol 43:990–995PubMedCrossRefGoogle Scholar
  172. 172.
    Yamaguchi H (2002) Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo. J Pharmacol Exp Ther 300:1063–1069PubMedCrossRefGoogle Scholar
  173. 173.
    Takanaga H, Ohnishi A, Yamada S, Matsuo H, Morimoto S, Shoyama Y, Ohtani H, Sawada Y (2000) Polymethoxylated flavones in orange juice are inhibitors of P-glycoprotein but not cytochrome P450 3A4. J Pharmacol Exp Ther 293:230–236PubMedGoogle Scholar
  174. 174.
    Fuhr U, Anders EM, Mahr G, Sorgel F, Staib AH (1992) Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob Agents Chemother 36:942–948PubMedPubMedCentralCrossRefGoogle Scholar
  175. 175.
    Carbó M, Segura J, De la Torre R, Badenas JM, Camí J (1989) Effect of quinolones on caffeine disposition. Clin Pharmacol Ther 45:234–240PubMedCrossRefGoogle Scholar
  176. 176.
    Healy DP, Polk RE, Kanawati L, Rock DT, Mooney ML (1989) Interaction between oral ciprofloxacin and caffeine in normal volunteers. Antimicrob Agents Chemother 33:474–478PubMedPubMedCentralCrossRefGoogle Scholar
  177. 177.
    Staib AH, Harder S, Mieke S, Beer C, Stille W, Shah P (1987) Gyrase-inhibitors impair caffeine elimination in man. Methods Find Exp Clin Pharmacol 9:193–198PubMedGoogle Scholar
  178. 178.
    Wright DH, Pietz SL, Konstantinides FN, Rotschafer JC (2000) Decreased in vitro fluoroquinolone concentrations after admixture with an enteral feeding formulation. J Parenter Enter Nutr 24:42–48CrossRefGoogle Scholar
  179. 179.
    Mueller BA, Brierton DG, Abel SR, Bowman L (1994) Effect of enteral feeding with ensure on oral bioavailabilities of ofloxacin and ciprofloxacin. Antimicrob Agents Chemother 38:2101–2105PubMedPubMedCentralCrossRefGoogle Scholar
  180. 180.
    Yuk JH, Nightingale CH, Sweeney KR, Quintiliani R, Lettieri JT, Frost RW (1989) Relative bioavailability in healthy volunteers of ciprofloxacin administered through a nasogastric tube with and without enteral feeding. Antimicrob Agents Chemother 33:1118–1120PubMedPubMedCentralCrossRefGoogle Scholar
  181. 181.
    Burkhardt O, Stass H, Thuss U, Borner K, Welte T (2005) Effects of enteral feeding on the oral bioavailability of moxifloxacin in healthy volunteers. Clin Pharmacokinet 44:969–976PubMedCrossRefGoogle Scholar
  182. 182.
    Healy DP, Brodbeck MC, Clendening CE (1996) Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes. Antimicrob Agents Chemother 40:6–10PubMedPubMedCentralGoogle Scholar
  183. 183.
    Deppermann KM, Lode H (1993) Fluoroquinolones: interaction profile during enteral absorption. Drugs 45(Suppl 3):65–72PubMedCrossRefGoogle Scholar
  184. 184.
    Lange H, Eggers R, Bircher J (1988) Increased systemic availability of albendazole when taken with a fatty meal. Eur J Clin Pharmacol 34:315–317PubMedCrossRefGoogle Scholar
  185. 185.
    Dayan AD (2003) Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics. Acta Trop 86:141–159PubMedCrossRefGoogle Scholar
  186. 186.
    Winstanley PA, Orme ML (1989) The effects of food on drug bioavailability. Br J Clin Pharmacol 28:621–628PubMedPubMedCentralCrossRefGoogle Scholar
  187. 187.
    Anonymous. MINTEZOL (thiabendazole) [package insert]. West Point, PA; Merck & Co., Inc. Revised June 2003. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/16096slr033,16097slr026_mintezol_lbl.pdf. Accessed 20 March 2017
  188. 188.
    Anonymous. STROMECTOL (ivermectin) [package insert]. Whitehouse Station, NJ; Merck & Co., Inc. Revised October 2003. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050742s026lbl.pdf. Accessed 20 March 2017
  189. 189.
    Anonymous. BILTRICIDE (praziquantel) [package insert]. Wayne, NJ; Bayer Healthcare Pharmaceuticals, Inc. Revised August 2010. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018714s012lbl.pdf. Accessed 20 March 2017
  190. 190.
    Castro N, Jung H, Medina R, Gonzalez-Esquivel D, Lopez M, Sotelo J (2002) Interaction between grapefruit juice and praziquantel in humans. Antimicrob Agents Chemother 46:1614–1616PubMedPubMedCentralCrossRefGoogle Scholar
  191. 191.
    Anonymous. QUALAQUIN (quinine sulfate) [package insert]. Philadelphia, PA; AR Scientific, Inc. Revised June 2008. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021799s008lbl.pdf. Accessed 20 March 2017
  192. 192.
    Anonymous. PLAQUENIL (hydroxychloroquine) [package insert]. Bridgewater, NJ; Sanofi-Aventis, LLC. Revised October 2006. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/009768s041lbl.pdf. Accessed 20 March 2017
  193. 193.
    Anonymous. DARAPRIM (pyrimethamine) [package insert]. Greenville, NC; DSM Pharmaceuticals, Inc. Revised March 2003. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/08578slr016_daraprim_lbl.pdf. Accessed 20 March 2017
  194. 194.
    Anonymous. FANSIDAR (sulfadoxine and pyrimethamine) [package insert]. Nutley, NJ; Roche Pharmaceuticals, Inc. Revised February 2004. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/18557slr015_fansidar_lbl.pdf. Accessed 20 March 2017
  195. 195.
    Anonymous. COARTEM (artemether/lumefantrine) [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corporation. Revised March 2015. Available from: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/coartem.pdf. Accessed 20 March 2017
  196. 196.
    Anonymous. LARIAM (mefloquine hydrochloride) [package insert]. Nutley, NJ; Roche Pharmaceuticals, Inc. Revised August 2008. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019591s026s028lbl.pdf. Accessed 20 March 2017
  197. 197.
    Freeman CD, Klutman NE, Lamp KC, Dall LH, Strayer AH (1998) Relative bioavailability of atovaquone suspension when administered with an enteral nutrition supplement. Ann Pharmacother 32:1004–1007PubMedCrossRefGoogle Scholar
  198. 198.
    Anonymous. MEPRON (atovaquone) [package insert]. Research Triangle Park, NC; GalxoSmithKline . Revised May 2008. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020500s010lbl.pdf. Accessed 20 March 2017
  199. 199.
    Anonymous. MALARONE (atovaquone and proguanil hydrochloride) [package insert]. Research Triangle Park, NC; GalxoSmithKline . Revised July 2016. Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Malarone/pdf/MALARONE.PDF Accessed 20 March 2017
  200. 200.
    Anonymous. CLEOCIN HCL (clindamycin hydrochloride) [package insert]. Kalamazoo, MI; Pharmacia and Upjohn Company. Revised 2009. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050162s085lbl.pdf. Accessed 20 March 2017
  201. 201.
    Anonymous. DIFICID (fidaxomicin) [package insert]. Whitehouse Station, NJ; Merck & Co., Inc. Revised December 2015. Available from: https://www.merck.com/product/usa/pi_circulars/d/dificid/dificid_pi.pdf. Accessed 20 March 2017
  202. 202.
    Anonymous. MONUROL (fosfomycin tromethamine) [package insert]. St. Louis, MO; Forest Pharmaceuticals, Inc. Revised July 2007. Available from http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050717s005lbl.pdf. Accessed 11 May 2015
  203. 203.
    Anonymous. ALINIA (nitazoxanide) [package insert]. Tampa, FL; Romark Pharmaceuticals, LC. Revised June 2005. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021818lbl.pdf. Accessed 20 March 2017
  204. 204.
    D’Arcy PF (1985) Nitrofurantoin. Ann Pharmacother 19:540–547Google Scholar
  205. 205.
    Bates TR, Sequeira JA, Tembo AV (1974) Effect of food on nitrofurantoin absorption. Clin Pharmacol Ther 16:63–68PubMedCrossRefGoogle Scholar
  206. 206.
    Rosenberg HA, Bates TR (1976) The influence of food on nitrofurantoin bioavailability. Clini PharmacolTher 20:227–232Google Scholar
  207. 207.
    Anonymous. TINDAMAX (tinidazole) [package insert]. Mumbai, India; Unique Pharmaceuticals Laboratories. Revised May 2007. Available from: https://www.risingpharma.com/Files/Prescribing-Info/Package%20Insert-Tinidazole%20Tablets-250mg-500mg.pdf. Accessed 20 March 2017
  208. 208.
    Antal EJ, Hendershot PE, Batts DH, Sheu W-P, Hopkins NK, Donaldson KM (2001) Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to oral tyramine. J Clin Pharmacol 41:552–562PubMedCrossRefGoogle Scholar
  209. 209.
    Flanagan S, Bartizal K, Minassian SL, Fang E, Prokocimer P (2013) In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions. Antimicrob Agents Chemother 57:3060–3066PubMedPubMedCentralCrossRefGoogle Scholar
  210. 210.
    Anonymous. XIFAXAN (rifaximin) [package insert]. Morrisville, NJ; Salix Pharmaceuticals, Inc. Revised 2010. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022554lbl.pdf. Accessed 20 March 2017
  211. 211.
    Anonymous. Sulfadiazine [package insert]. New Hyde Park, NY; Eon Labs, Inc. Revised March 2016. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10549cba-9c15-4d2e-a68c-5afbc178591d. Accessed 20 March 2017
  212. 212.
    Anonymous. BACTRIM (sulfamethoxazole and trimethoprim) [package insert]. Philadelphia, PA; Mutual Pharmaceutical Company, Inc. Revised June 2013. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017377s068s073lbl.pdf. Accessed 20 March 2017
  213. 213.
    Anonymous. VANCOCIN (vancomycin hydrochloride) [package insert]. Exton, PA; ViroPharma, Inc. Revised December 2011. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050606s028lbl.pdf. Accessed 20 March 2017
  214. 214.
    Melander A, Danielson K, Hanson A, Jansson L, Rerup C, Scherstén B, Thulin T, Wåhlin E (2009) Reduction of isoniazid bioavailability in normal men by concomitant intake of food. Acta Med Scand 200:93–97CrossRefGoogle Scholar
  215. 215.
    Self TH, Chrisman CR, Baciewicz AM, Bronze MS (1999) Isoniazid drug and food interactions. Am J Med Sci 317:304–311PubMedCrossRefGoogle Scholar
  216. 216.
    Smith CK (1978) Isoniazid and reaction to cheese. Ann Intern Med 88:520PubMedCrossRefGoogle Scholar
  217. 217.
    Baciewicz AM, Self TH (1985) Isoniazid interactions. South Med J 78:714–718PubMedCrossRefGoogle Scholar
  218. 218.
    Hauser MJ, Baier H (1982) Interactions of isoniazid with foods. Drug Intell Clin Pharm 16:617–618PubMedCrossRefGoogle Scholar
  219. 219.
    Siegler D (1974) Effect of meals on rifampicin absorption. Lancet 304:197–198CrossRefGoogle Scholar
  220. 220.
    Ameer B, Polk RE, Kline BJ, Grisafe JP (1982) Effect of food on ethambutol absorption. Clin Pharm 1:156–158PubMedGoogle Scholar
  221. 221.
    van Heeswijk RP, Dannemann B, Hoetelmans RM (2014) Bedaquiline: a review of human pharmacokinetics and drug-drug interactions. J Antimicrob Chemother 69:2310–2318PubMedCrossRefGoogle Scholar
  222. 222.
    Anonymous. SIRTURO (bedaquiline) [package insert]. Titusville, NJ; Janssen Therapeutics, LP. Revised December 2012. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/204384s000lbl.pdf. Accessed 20 March 2017
  223. 223.
    Holdiness MR (1984) Clinical pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet 9:511–544PubMedCrossRefGoogle Scholar
  224. 224.
    Anonymous. PASER (aminosalicyclic acid delayed-release granules) [package insert]. Princeton, NJ; Jacobus Pharmaceutical Company, Inc. Revised July 1996. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f2753dc-5f0c-4f49-9335-e519afb69ba6. Accessed 20 March 2017
  225. 225.
    Anonymous. CYCLOSERINE (cycloserine) [package insert]. West Lafayette, IN; The Chao Center for Industrial Pharmacy and Contract Manufacturing. Revised October 2011. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10727aa8-a03e-4b61-9a80-a024cb4a2d28. Accessed 20 March 2017
  226. 226.
    Venkatesan K (1989) Clinical pharmacokinetic considerations in the treatment of patients with leprosy. Clin Pharmacokinet 16:365–386PubMedCrossRefGoogle Scholar
  227. 227.
    Anonymous. TRECATOR (ethionamide) [package insert]. Philadelphia, PA; Wyeth Pharmaceuticals, Inc. Revised December 2005. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/013026s024lbl.pdf. Accessed 20 March 2017
  228. 228.
    Zvada SP, Van Der Walt JS, Smith PJ, Fourie PB, Roscigno G, Mitchison D, Simonsson US, McIlleron HM (2010) Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers. Antimicrob Agents Chemother 54:3390–3394PubMedPubMedCentralCrossRefGoogle Scholar
  229. 229.
    Chan SL, Yew WW, Porter JH, McAdam KP, Allen BW, Dickinson JM, Ellard GA, Mitchison DA (1994) Comparison of Chinese and Western rifapentines and improvement of bioavailability by prior taking of various meals. Int J Antimicrob Agents 3:267–274PubMedCrossRefGoogle Scholar
  230. 230.
    Anonymous. PRIFTIN (rifapentine) [package insert]. Bridgewater, NJ; Sanofi-Aventis, LLC. Revised December 2014. Available from: http://products.sanofi.us/priftin/priftin.pdf. Accessed 20 March 2017
  231. 231.
    Anonymous. DAPSONE (dapsone) [package insert]. Princeton, NJ; Jacobus Pharmaceutical Company, Inc. Revised July 2011. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0792169d-c6f9-4af0-93ae-b75d710c47a9. Accessed 20 March 2017
  232. 232.
    Teo SK, Colburn WA, Tracewell WG, Kook KA, Stirling DI, Jaworsky MS, Scheffler MA, Thomas SD, Laskin OL (2004) Clinical pharmacokinetics of thalidomide. Clin Pharmacokinet 43:311–327PubMedCrossRefGoogle Scholar
  233. 233.
    Anonymous. THALOMID (thalidomide) [package insert]. Summit, NJ; Celgene Corporation. Revised January 2017. Available from: https://www.celgene.com/content/uploads/thalomid-pi.pdf. Accessed 20 March 2017
  234. 234.
    Holdiness MR (1989) Clinical pharmacokinetics of clofazimine. A review. Clin Pharmacokinet 16:74–85PubMedCrossRefGoogle Scholar
  235. 235.
    Schaad-Lanyi Z, Dieterle W, Dubois JP, Theobald W, Vischer W (1987) Pharmacokinetics of clofazimine in healthy volunteers. Int J Lepr Other Mycobact Dis 55:9–15PubMedGoogle Scholar
  236. 236.
    Anonymous. LAMPRENE (clofazimine) [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corporation. Revised May 2006. Available from: https://www.drugs.com/pro/lamprene.html. Accessed 20 March 2017
  237. 237.
    Anonymous. ANCOBON (flucytosine) [package insert]. Bridgewater, NJ; Valeant Pharmaceuticals, LLC. Revised November 2013. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aea0df00-a88c-4a16-abcf-750f3ff2004e. Accessed 20 March 2017
  238. 238.
    Anonymous. LAMISIL (terbinafine) [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corportation. Revised January 2017. Available from: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/Lamisil_tablets.pdf. Accessed 20 March 2017
  239. 239.
    Lelawongs P, Barone JA, Colaizzi JL, Hsuan AT, Mechlinski W, Legendre R, Guarnieri J (1988) Effect of food and gastric acidity on absorption of orally administered ketoconazole. Clin Pharm 7:228–235PubMedGoogle Scholar
  240. 240.
    Mannisto PT, Mantyla R, Nykanen S, Lamminsivu U, Ottoila P (1982) Impairing effect of food on ketoconazole absorption. Antimicrob Agents Chemother 21:730–733PubMedPubMedCentralCrossRefGoogle Scholar
  241. 241.
    Wishart JM (1987) The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection. J Am Acad Dermatol 17:220–223PubMedCrossRefGoogle Scholar
  242. 242.
    Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van de Velde V (1993) Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother 37:778–784PubMedPubMedCentralCrossRefGoogle Scholar
  243. 243.
    Lange D, Pavao JH, Wu J, Klausner M (1997) Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2Blockers. J Clin Pharmacol 37:535–540PubMedCrossRefGoogle Scholar
  244. 244.
    Jaruratanasirikul S, Kleepkaew A (1997) Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. Eur J Clin Pharmacol 52:235–237PubMedPubMedCentralCrossRefGoogle Scholar
  245. 245.
    Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H (1998) Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects. Int J Clin Pharmacol Ther 36:306–308PubMedPubMedCentralGoogle Scholar
  246. 246.
    Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M (1999) Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers. Ther Drug Monit 21:304–309PubMedCrossRefGoogle Scholar
  247. 247.
    Gubbins PO, McConnell SA, Gurley BJ, Fincher TK, Franks AM, Williams DK, Penzak SR, Saccente M (2004) Influence of grapefruit juice on the systemic availability of itraconazole oral solution in healthy adult volunteers. Pharmacotherapy 24:460–467PubMedCrossRefGoogle Scholar
  248. 248.
    Sansone-Parsons A, Krishna G, Calzetta A, Wexler D, Kantesaria B, Rosenberg MA, Saltzman MA (2006) Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother 50:1881–1883PubMedPubMedCentralCrossRefGoogle Scholar
  249. 249.
    Krishna G, Ma L, Vickery D, Yu X, Wu I, Power E, Beresford E, Komjathy S (2009) Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother 53:4749–4752PubMedPubMedCentralCrossRefGoogle Scholar
  250. 250.
    Wiederhold NP (2016) Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections. Clin Pharmacol 8:1–8PubMedGoogle Scholar
  251. 251.
    Anonymous. NOXAFIL (posaconazole) [package insert]. Whitehouse Station, NJ; Merck & Co., Inc. Revised March 2017. Available from: https://www.merck.com/product/usa/pi_circulars/n/noxafil/noxafil_pi.pdf. Accessed 20 March 2017
  252. 252.
    Kraft WK, Chang PS, van Iersel ML, Waskin H, Krishna G, Kersemaekers WM (2014) Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects. Antimicrob Agents Chemother 58:4020–4025PubMedPubMedCentralCrossRefGoogle Scholar
  253. 253.
    Yamazaki T, Desai A, Goldwater R, Han D, Howieson C, Akhtar S, Kowalski D, Lademacher C, Pearlman H, Rammelsberg D, Townsend R (2017) Pharmacokinetic effects of isavuconazole coadministration with the cytochrome P450 enzyme substrates bupropion, repaglinide, caffeine, dextromethorphan, and methadone in healthy subjects. Clin Pharmacol Drug Dev 6:54–65PubMedCrossRefGoogle Scholar
  254. 254.
    Bijanzadeh M, Mahmoudian M, Salehian P, Khazainia T, Eshghi L, Khosravy A (1990) The bioavailability of griseofulvin from microsized and ultramicrosized tablets in nonfasting volunteers. Indian J Physiol Pharmacol 34:157–161PubMedGoogle Scholar
  255. 255.
    Crounse RG (1961) Human pharmacology of griseofulvin: the effect of fat intake on gastrointestinal absorption11from the Department of Dermatology, University of Miami Medical School, Miami, Florida. J Investig Dermatol 37:529–533PubMedCrossRefGoogle Scholar
  256. 256.
    Hartman NR, Yarchoan R, Pluda JM, Thomas RV, Marczyk KS, Broder S, Johns DG (1990) Pharmacokinetics of 2′, 3′-dideoxyadenosine and 2′, 3′-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin Pharmacol Ther 47:647–654PubMedCrossRefGoogle Scholar
  257. 257.
    Knupp CA, Shyu WC, Dolin R, Valentine FT, McLaren C, Martin RR, Pittman KA, Barbhaiya RH (1991) Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome—related complex. Clin Pharmacol Ther 49:523–535PubMedCrossRefGoogle Scholar
  258. 258.
    McGowan JJ, Tomaszewski JE, Cradock J, Hoth D, Grieshaber CK, Broder S, Mitsuya H (1990) Overview of the preclinical development of an antiretroviral drug, 2′,3′-dideoxyinosine. Clin Infect Dis 12:S513–S521CrossRefGoogle Scholar
  259. 259.
    Damle BD, Kaul S, Behr D, Knupp C (2002) Bioequivalence of two formulations of didanosine, encapsulated enteric-coated beads and buffered tablet, in healthy volunteers and HIV-infected subjects. J Clin Pharmacol 42:791–797PubMedCrossRefGoogle Scholar
  260. 260.
    Anonymous. VIDEX EC (didanosine) [package insert]. Princeton, NJ; Bristol-Myers Squibb. Revised August 2015. Available from: https://packageinserts.bms.com/pi/pi_videx_ec.pdf. Accessed 20 March 2017
  261. 261.
    Klecker RW, Collins JM, Yarchoan R, Thomas R, Jenkins JF, Broder S, Myers CE (1987) Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther 41:407–412PubMedCrossRefGoogle Scholar
  262. 262.
    Sahai J, Gallicano K, Garber G, McGilveray I, Hawley-Foss N, Turgeon N, Cameron DW (1992) The effect of a protein meal on zidovudine pharmacokinetics in HIV- infected patients. Br J Clin Pharmacol 33:657–660PubMedPubMedCentralCrossRefGoogle Scholar
  263. 263.
    Unadkat JD, Collier AC, Crosby SS, Cummingst D, Opheimt KE, Coreyt L (1990) Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high-fat meal. AIDS 4:229–232PubMedCrossRefGoogle Scholar
  264. 264.
    Lotterer E, Ruhnke M, Trautmann M, Beyer R, Bauer FE (1991) Decreased and variable systemic availability of zidovudine in patients with AIDS if administered with a meal. Eur J Clin Pharmacol 40:305–308PubMedCrossRefGoogle Scholar
  265. 265.
    Anonymous. ZERIT (stavudine) [package insert]. Princeton, NJ; Bristol-Myers Squibb. Revised December 2012. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020412s029,020413s020lbl.pdf. Accessed 20 March 2017
  266. 266.
    Foster RH, Faulds D (1998) Abacavir. Drugs 55:729–736PubMedCrossRefGoogle Scholar
  267. 267.
    Yuen GJ, Lou Y, Thompson NF, Otto VR, Allsup TL, Mahony WB, Hutman HW (2001) Abacavir/Lamivudine/Zidovudme as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption. J Clin Pharmacol 41:277–288PubMedCrossRefGoogle Scholar
  268. 268.
    Weller S, Chen S, Borland J, Savina P, Wynne B, Piscitelli SC (2014) Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food. J Acquir Immune Defic Syndr 66:393–398PubMedCrossRefGoogle Scholar
  269. 269.
    Anonymous. EMTRIVA (emtricitabine) [package insert]. Foster City, CA; Gilead Sciences, Inc. Revised November 2012. Available from: http://www.gilead.com/~/media/files/pdfs/medicines/hiv/emtriva/emtriva_pi.pdf. Accessed 20 March 2017
  270. 270.
    Anonymous. TRUVADA (emtricitabine/tenofovir disoproxil fumurate) [package insert]. Foster City, CA; Gilead Sciences, Inc. Revised April 2016. Available from: http://www.gilead.com/~/media/files/pdfs/medicines/hiv/truvada/truvada_pi.pdf. Accessed 20 March 2017
  271. 271.
    Anonymous. VIREAD (tenofovir disoproxil fumurate) [package insert]. Foster City, CA; Gilead Sciences, Inc. Revised February 2016. Available from: http://gilead.com/~/media/files/pdfs/medicines/liver-disease/viread/viread_pi.pdf. Accessed 20 March 2017
  272. 272.
    Barditch-Crovo P, Deeks SG, Collier A, Safrin S, Coakley DF, Miller M, Kearney BP, Coleman RL, Lamy PD, Kahn JO, McGowan I, Lietman PS (2001) Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 45:2733–2739PubMedPubMedCentralCrossRefGoogle Scholar
  273. 273.
    Anonymous. VEMLIDY (tenofovir alafenamide) [package insert]. Foster City, CA; Gilead Sciences, Inc. Revised November 2016. Available from: https://www.gilead.com/~/media/files/pdfs/medicines/liver-disease/vemlidy/vemlidy_pi.pdf?la=en. Accessed 20 March 2017
  274. 274.
    Anonymous. SUSTIVA (efavirenz) [package insert]. Princeton, NJ; Bristol-Myers Squibb. Revised January 2017. Available from: https://packageinserts.bms.com/pi/pi_sustiva.pdf. Accessed 20 March 2017
  275. 275.
    Anonymous. ATRIPLA (efavirenz/emtricitabine/tenofovir disoproxil fumurate) [package insert]. Foster City, CA; Gilead Sciences, Inc. Revised February 2016. Available from: http://packageinserts.bms.com/pi/pi_atripla.pdf. Accessed 20 March 2017
  276. 276.
    Beach JW (1998) Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions. Clin Ther 20:2–25; discussion lPubMedCrossRefGoogle Scholar
  277. 277.
    Anonymous. INTELENCE (etravirine) [package insert]. Titusville, NJ; Janssen Pharmaceuticals, Inc. Revised August 2014. Available from: http://www.intelence.com/shared/product/intelence/prescribing-information.pdf. Accessed 20 March 2017
  278. 278.
    Anonymous, Hoetelmans R, Van Heeswijk R, Kestens D, et al (2005) Effect of food on and multiple-dose pharmacokinetics of TMC278 as an oral tablet formulation. Third International AIDS Conference, Rio de Janeiro, Brazil, July 2005. Abstract TuPe3.1 B10Google Scholar
  279. 279.
    Williams GC, Sinko PJ (1999) Oral absorption of the HIV protease inhibitors: a current update. Adv Drug Deliv Rev 39:211–238PubMedCrossRefGoogle Scholar
  280. 280.
    Anonymous. CRIXIVAN (indinavir) [package insert]. Whitehouse Station, NJ; Merck & Co., Inc. Revised September 2016. Available from: https://www.merck.com/product/usa/pi_circulars/c/crixivan/crixivan_pi.pdf. Accessed 20 March 2017
  281. 281.
    Penzak SR, Acosta EP, Turner M, Edwards DJ, Hon YY, Desai HD, Jann MW (2002) Effect of seville orange juice and grapefruit juice on indinavir pharmacokinetics. J Clin Pharmacol 42:1165–1170PubMedCrossRefGoogle Scholar
  282. 282.
    Shelton MJ, Wynn HE, Hewitt RG, DiFrancesco R (2001) Effects of grapefruit juice on pharmacokinetic exposure to indinavir in HIV-positive subjects. J Clin Pharmacol 41:435–442PubMedCrossRefGoogle Scholar
  283. 283.
    Noble S, Faulds D (1996) Saquinavir. Drugs 52:93–112PubMedCrossRefGoogle Scholar
  284. 284.
    Kupferschmidt HHT, Fattinger KE, Ha HR, Follath F, Krähenbühl S (2003) Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol 45:355–359CrossRefGoogle Scholar
  285. 285.
    Anonymous. INVIRASE (saquinavir mesylate) [package insert]. Nutley, NJ; Roche Pharmaceuticals, Inc. Revised April 2010. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020628s032,021785s009lbl.pdf. Accessed 20 March 2017
  286. 286.
    Kenyon CJ, Brown F, McClelland GR, Wilding IR (1998) The use of pharmacoscintigraphy to elucidate food effects observed with a novel protease inhibitor (saquinavir). Pharm Res 15:417–422PubMedCrossRefGoogle Scholar
  287. 287.
    Perry CM, Benfield P (1997) Nelfinavir. Drugs 54:81–87PubMedCrossRefGoogle Scholar
  288. 288.
    Anonymous. LEXIVA (fosamprenavir calcium) [package insert]. Research Triangle Park, NC; GlaxoSmithKline. Revised September 2009. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021548s021,022116s005lbl.pdf. Accessed 20 March 2017
  289. 289.
    Anonymous. KALETRA (lopinavir and ritonavir) [package insert]. Chicago, IL; AbbVie, Inc. Revised November 2016. Available from: http://www.rxabbvie.com/pdf/kaletratabpi.pdf. Accessed 20 March 2017
  290. 290.
    Klein CE, Chiu YL, Awni W, Zhu T, Heuser RS, Doan T, Breitenbach J, Morris JB, Brun SC, Hanna GJ (2007) The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr 44:401–410PubMedCrossRefGoogle Scholar
  291. 291.
    Anonymous. REYATAZ (atazanavir) [package insert]. Princeton, NJ; Bristol-Myers Squibb. Revised September 2016. Available from: https://packageinserts.bms.com/pi/pi_reyataz.pdf. Accessed 20 March 2017
  292. 292.
    Anonymous. APTIVUS (tipranavir) [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals, Inc. Revised September 2016. Available from: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Aptivus/10003515%20US%2001.pdf?DMW_FORMAT=pdf. Accessed 20 March 2017
  293. 293.
    Kakuda TN, Van De Casteele T, Petrovic R, Neujens M, Salih H, Opsomer M, Hoetelmans RM (2014) Bioequivalence of a darunavir/cobicistat fixed-dose combination tablet versus single agents and food effect in healthy volunteers. Antivir Ther 19:597–606PubMedCrossRefGoogle Scholar
  294. 294.
    Kiser JJ, Bumpass JB, Meditz AL, Anderson PL, Bushman L, Ray M, Predhomme JA, Rower J, Mawhinney S, Brundage R (2010) Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers. Antimicrob Agents Chemother 54:4999–5003PubMedPubMedCentralCrossRefGoogle Scholar
  295. 295.
    Cottrell ML, Hadzic T, Kashuba AD (2013) Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet 52:981–994PubMedPubMedCentralCrossRefGoogle Scholar
  296. 296.
    Song I, Borland J, Arya N, Wynne B, Piscitelli S (2015) Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects. J Clin Pharmacol 55:490–496PubMedPubMedCentralCrossRefGoogle Scholar
  297. 297.
    Patel P, Song I, Borland J, Patel A, Lou Y, Chen S, Wajima T, Peppercorn A, Min SS, Piscitelli SC (2011) Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers. J Antimicrob Chemother 66:1567–1572PubMedCrossRefGoogle Scholar
  298. 298.
    Ramanathan S, Mathias AA, German P, Kearney BP (2011) Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet 50:229–244PubMedCrossRefGoogle Scholar
  299. 299.
    Anonymous. STRIBILD (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumurate) [package insert]. Foster City, CA; Gilead Sciences, Inc. Revised September 2016. Available from: http://www.gilead.com/~/media/files/pdfs/medicines/hiv/stribild/stribild_pi_old.pdf. Accessed 20 March 2017
  300. 300.
    Anonymous. GENVOYA (elvitegravir, cobicistat, emtricitabine, tenofovir alefenamide) [package insert]. Foster City, CA; Gilead Sciences, Inc. Revised February 2017. Available from: https://www.gilead.com/~/media/files/pdfs/medicines/hiv/genvoya/genvoya_pi.pdf?la=en. Accessed 20 March 2017
  301. 301.
    Cattaneo D, Baldelli S, Minisci D, Meraviglia P, Clementi E, Galli M, Gervasoni C (2016) When food can make the difference: the case of elvitegravir-based co-formulation. Int J Pharm 512:301–304PubMedCrossRefGoogle Scholar
  302. 302.
    Anonymous. Food and drug administration center for drug evaluation and research clinical pharmacology and biopharmaceutics review: Application Number 22–128. Maraviroc. 19 December 2006. Available from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022128s000_ClinPharmR.pdf. Accessed 19 March 2017
  303. 303.
    Anonymous. HEPSERA (adefovir) [package insert]. Foster City, CA; Gilead Sciences, Inc. Revised November 2012. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021449s020lbl.pdf. Accessed 20 March 2017
  304. 304.
    Anonymous. BARACLUDE (entecavir) [package insert]. New York, NY; Bristol-Myers Squibb. Revised August 2015. Available from: http://packageinserts.bms.com/pi/pi_baraclude.pdf. Accessed 20 March 2017
  305. 305.
    Anonymous. TYZEKA (telbivudine) [package insert]. East Hanover, NJ; Novartis Pharmaceuticals, Corp. Revised January 2013. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022011s013lbl.pdf. Accessed 20 March 2017
  306. 306.
    Li L, Koo SH, Limenta LM, Han L, Hashim KB, Quek HH, Lee EJ (2009) Effect of dietary purines on the pharmacokinetics of orally administered ribavirin. J Clin Pharmacol 49:661–667PubMedCrossRefGoogle Scholar
  307. 307.
    Chang MH, Gordon LA, Fung HB (2012) Boceprevir: a protease inhibitor for the treatment of hepatitis C. Clin Ther 34:2021–2038PubMedCrossRefGoogle Scholar
  308. 308.
    Anonymous. VICTRELIS (boceprevir) [package insert]. Whitehouse Station, NJ; Merck & Co, Inc. Revised January 2017. Available from: https://www.merck.com/product/usa/pi_circulars/v/victrelis/victrelis_pi.pdf. Accessed 20 March 2017
  309. 309.
    Kiang TK, Wilby KJ, Ensom MH (2013) Telaprevir: clinical pharmacokinetics, pharmacodynamics, and drug-drug interactions. Clin Pharmacokinet 52:487–510PubMedCrossRefGoogle Scholar
  310. 310.
    Anonymous. INCIVEK (telapravir) [package insert]. Cambridge, MA; Vertex Pharmaceuticals, Inc. Revised December 2012. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201917s007lbl.pdf. Accessed 20 March 2017
  311. 311.
    Anonymous. OLYSIO (simeprevir) [package insert]. Titusville, NJ; Janssen Therapeutics. Revised February 2017. Available from: https://www.olysio.com/shared/product/olysio/prescribing-information.pdf. Accessed 20 March 2017
  312. 312.
    Anonymous. VIEKIRA PAK (ombitasvir, paritaprevir, ritonavir, and dasabuvir) [package insert]. Chicago, IL; AbbVie, Inc. Revised February 2017. Available from: http://www.rxabbvie.com/pdf/viekirapak_pi.pdf. Accessed 20 March 2017
  313. 313.
    King JR, Zha J, Khatri A, Dutta S, Menon RM (2017) Clinical pharmacokinetics of dasabuvir. Clin Pharmacokinet.  https://doi.org/10.1007/s40262-017-0519-3
  314. 314.
    Anonymous. ZEPATIER (elbasvir and grazoprevir) [package insert]. Whitehouse Station, NJ; Merck & Co, Inc. Revised February 2017. Available from: https://www.merck.com/product/usa/pi_circulars/z/zepatier/zepatier_pi.pdf. Accessed 20 March 2017
  315. 315.
    Aoki FY, Sitar DS (1988) Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet 14:35–51PubMedCrossRefGoogle Scholar
  316. 316.
    Anonymous. FLUMADINE (rimantadine) [package insert]. Saint Louis, MO; Forest Pharmaceuticals, Inc. Revised April 2010. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019649s015lbl.pdf. Accessed 20 March 2017
  317. 317.
    Acosta EP, Fletcher CV (1997) Valacyclovir. Ann Pharmacother 31:185–191PubMedCrossRefGoogle Scholar
  318. 318.
    Anonymous. ZOVIRAX (acyclovir) [package insert]. Research Triangle Park, NC; GlaxoSmithKline. Revised June 2005. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/018828s030,020089s019,019909s020lbl.pdf. Accessed 20 March 2017
  319. 319.
    Jung D, Dorr A (1999) Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. J Clin Pharmacol 39:800–804PubMedCrossRefGoogle Scholar
  320. 320.
    Pescovitz MD, Rabkin J, Merion RM, Paya CV, Pirsch J, Freeman RB, O’Grady J, Robinson C, To Z, Wren K, Banken L, Buhles W, Brown F (2000) Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 44:2811–2815PubMedPubMedCentralCrossRefGoogle Scholar
  321. 321.
    Fuller RK (1979) Disulfiram for the treatment of alcoholism. Ann Intern Med 90:901PubMedCrossRefGoogle Scholar
  322. 322.
    Adams WL (1995) Interactions between alcohol and other drugs. Int J Addict 30:1903–1923PubMedCrossRefGoogle Scholar
  323. 323.
    Kannangara DW, Gallagher K, Lefrock JL (1984) Disulfiram-like reactions with newer cephalosporins: cefmenoxime. Am J Med Sci 287:45–47PubMedGoogle Scholar
  324. 324.
    Campbell B, Taylor JT, Haslett WL (1967) Anti-alcohol properties of metronidazole in rats. Exp Biol Med 124:191–195CrossRefGoogle Scholar
  325. 325.
    Edwards JA, Price J (1967) Metronidazole and human alcohol dehydrogenase. Nature 214:190–191PubMedCrossRefGoogle Scholar
  326. 326.
    Kline SS, Mauro VF, Forney RB, Freimer EH, Somani P (1987) Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia. Antimicrob Agents Chemother 31:1328–1331PubMedPubMedCentralCrossRefGoogle Scholar
  327. 327.
    Lassman HB, Hubbard JW, Chen BL, Puri SK (1992) Lack of interaction between cefpirome and alcohol. J Antimicrob Chemother 29:47–50PubMedCrossRefGoogle Scholar
  328. 328.
    McMahon FG, Noveck RJ (1982) Lack of disulfiram-like reactions with ceftizoxime. J Antimicrob Chemother 10:129–133PubMedCrossRefGoogle Scholar
  329. 329.
    Kitson TM (1987) The effect of cephalosporin antibiotics on alcohol metabolism: a review. Alcohol 4:143–148PubMedCrossRefGoogle Scholar
  330. 330.
    Uri JV, Parks DB (1983) Disulfiram-like reaction to certain cephalosporins. Ther Drug Monit 5:219–224PubMedCrossRefGoogle Scholar
  331. 331.
    Azarnoff DL (1974) Drug interactions: clinical significance. Clin Pharmacol Ther 16:986–988PubMedCrossRefGoogle Scholar
  332. 332.
    Heelon MW, White M (1998) Disulfiram-cotrimoxazole reaction. Pharmacotherapy 18:869–870PubMedGoogle Scholar
  333. 333.
    Anonymous. NORVIR (ritonavir) [package insert]. Chicago, IL; AbbVie, Inc. Revised December 2016. Available from: http://www.rxabbvie.com/pdf/norvirtab_pi.pdf. Accessed 20 March 2017

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Eric Wenzler
    • 1
  • Kelly Sprandel-Harris
    • 2
  • Keith A. Rodvold
    • 3
  1. 1.University of Illinois at Chicago, College of PharmacyChicagoUSA
  2. 2.Achaogen, IncSan FransiscoUSA
  3. 3.Colleges of Pharmacy and Medicine, University of Illinois at ChicagoChicagoUSA

Personalised recommendations